Scarica l'app Stockscreener
45.08
4.18%
-2.0644
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Moderna Inc Borsa (MRNA) Ultime notizie
Leading Companies Fueling Growth and Innovation in the Spikevax Market - openPR.com
Research Analysts Issue Forecasts for Moderna Q1 Earnings - MarketBeat
Salesforce Says Moderna Selects Agentforce Platform to Consolidate Commercial Operations - Moomoo
AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer - BioSpace
Moderna Gears Up to Report Q1 Earnings: Here's What to Expect - Yahoo Finance Singapore
Is Moderna (MRNA) Pricing Make Sense After 77% One-Year Surge And DCF Signal? - Yahoo Finance
CureVac Patent Suit Targets Moderna’s Spikevax Covid-19 Shots - Bloomberg Law News
Moderna shares dip amid rising selling pressure - Traders Union
Which Is the Better iShares ETF for Small-Cap Value Investing, ISCV or IWN? - The Motley Fool
Moderna, Inc. (MRNA) Stock Analysis: Navigating A 52-Week High Amidst Revenue Decline - DirectorsTalk Interviews
Moderna, Inc. (NASDAQ:MRNA) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Has $4.12 Million Position in Moderna, Inc. $MRNA - MarketBeat
M&T Bank Corp Acquires 240,400 Shares of Moderna, Inc. $MRNA - MarketBeat
MRNA Price Today: Moderna, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
CureVac sues Moderna for patent infringement over COVID-19 vaccines - Reuters
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate - Eagle-Tribune
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 - News-Press NOW
CureVac sues Moderna over mRNA vaccine patents - Investing.com
Moderna shares slide as traders digest recent EU vaccine clearance and refocus on funding/earnings overhangs - Quiver Quantitative
CureVac sues Moderna over mRNA vaccine patents By Investing.com - Investing.com Canada
Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
MRNA Technical Analysis | Trend, Signals & Chart Patterns | MODERNA INC (NASDAQ:MRNA) - ChartMill
Moderna (MRNA) Expected to Announce Earnings on Friday - MarketBeat
Moderna, Inc. (MRNA) Presents at ESCMID Global 2026Slideshow (NASDAQ:MRNA) 2026-04-23 - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
What does smart money think about Moderna (MRNA) stock (+1.11%) 2026-04-22Social Buzz - Cổng thông tin điện tử tỉnh Lào Cai
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
COVID vaccine report on cutting hospital visits blocked from publication in CDC journal - Seeking Alpha
Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial - Healthcare Dive
European Commission Approves MRNA's COVID-19-Influenza Combo Shot - Yahoo Finance
Moderna starts late-stage trial for bird flu vaccine - Seeking Alpha
Analyst recommendations: Meta, Amazon, Booking, Goldman Sachs, Moderna… - marketscreener.com
Moderna : ESCMID 2026 (mRNA-1273 & mRNA-1283 Effectiveness and safety of variant updated Covid vaccines) - marketscreener.com
Amid US ordeal, Moderna wins EU approval for flu/COVID-19 combo shot - BioSpace
Moderna Inc. stock (US60770K1034): Does its mRNA pivot beyond COVID now unlock sustainable growth? - AD HOC NEWS
Moderna Inc. (MRNA)Announces Accepted Oncology Clinical Data Presentations at 2026 ASCO Annual Meeting, Schedules Concurrent Investor WebcastFloat Short - UBND thành phố Hải Phòng
Moderna Inc. (MRNA) Secures European Commission Marketing Authorization for World’s First Combined Influenza-COVID mRNA Vaccine mCOMBRIAXCost Structure - UBND thành phố Hải Phòng
Moderna to Present at Upcoming Conferences in May 2026 - Investing News Network
Moderna (MRNA) Advances with Phase 3 Study of Influenza Vaccine - GuruFocus
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus
Moderna begins phase 3 trial of H5 bird flu vaccine candidate - Investing.com Canada
Moderna starts late-stage trial of bird flu vaccine in US, UK - Reuters
Moderna begins late-stage bird flu shot trial in U.S. and UK - Stock Titan
High-Yield Autocallable Notes Linked to Moderna (AMUB) — 1-Year Term - Stock Titan
Europe Clears First Flu/COVID Combo Shot From Moderna - Benzinga
Moderna Receives European Commission Marketing Authorization For mCOMBRIAX - TradingView
Moderna (MRNA) Secures EU Approval for mCOMBRIAX Vaccine - GuruFocus
Moderna: Ec Granted Marketing Authorization f - Moomoo
Moderna (MRNA) Secures EU Approval for mRNA Combination Vaccine - GuruFocus
Moderna wins EU approval for combined flu, COVID shot for older adults - Reuters
Moderna wins EC nod for mCOMBRIAX - The Pharma Letter
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting - Investing News Network
ESCMID Global 2026: repeat vaccination with mRNA-1010 safe and effective - Clinical Trials Arena
European Commission approves Moderna’s flu-COVID combo vaccine By Investing.com - Investing.com Canada
Moderna (MRNA.US) Receives EU Approval for Influenza and COVID-19 Combination Vaccine for Older Adults - AASTOCKS.com
Moderna granted EU nod for combined COVID-19 and flu vaccine - Seeking Alpha
European Commission approves Moderna’s flu-COVID combo vaccine - Investing.com
Cambridge drugmaker wins EU approval for combination shot amid FDA battles - The Business Journals
EU approves Moderna's dual flu-COVID vaccine - Breakingthenews.net
Moderna lines up melanoma and myeloma data for ASCO in Chicago - Stock Titan
3.17%
0.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):